Lung Cancer

SCC244, a highly selective MET inhibitor, demonstrated durable efficacy in patients with non–small cell lung cancer who harbored MET exon 14 skipping mutations.

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.

Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

The use of trilaciclib prior to chemotherapy resulted in a 50% reduction in the percent of patients with extensive-stage small cell lung cancer who had grade 3 or higher myelosuppressive hematologic adverse effects in at least 1 blood cell lineage.

Marketing authorization applications seeking the approval of tislelizumab in patients with advanced or metastatic esophageal squamous cell carcinoma following previous systemic chemotherapy and in select patients with non–small cell lung cancer have been submitted to the European Medicines Agency.

This publication highlights insights from expert stakeholders on the evolving therapeutic landscape of immunotherapy-based treatment regimens through a review of clinical scenarios of patients with non-small cell lung cancer.

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non­–small cell lung cancer.

Scott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.

Raymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.

This article surveils key advancements in the role of antibody-drug conjugates in solid tumors by examining important clinical trial findings on targeting Trop-2 in breast and lung cancers.

The combination of eftilagimod alpha and pembrolizumab was found to produce an encouraging early overall survival rate of 73% at the 6-month landmark when used as second-line treatment in patients with PD-1/PD-L1–refractory, metastatic non–small cell lung cancer, according to data from part B of the phase 2 TACTI-002 trial.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

The addition of the anti-TIGIT immunotherapy tiragolumab to atezolizumab plus carboplatin/etoposide failed to significantly improve progression-free survival over atezolizumab/chemotherapy alone when used in the frontline treatment of patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase 3 SKYSCRAPER-02 trial.

The European Medicines Agency has validated its type II variation application for nivolumab in combination with chemotherapy for use in the neoadjuvant treatment of patients with unresectable stage IB to IIIA non–small cell lung cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

A panel of lung cancer experts from China, South Korea, and Japan share their insights on how they care for their patients with resectable EGFR-positive non–small cell lung cancer.

Horacio J. Asbun, MD, discusses the importance of multidisciplinary approaches in pancreatic cancer.

Rupesh Rajesh Kotecha, MD, discusses the use of magnetic resonance–guided radiotherapy in lung cancer.

Pembrolizumab was found to significantly improve disease-free survival vs placebo when used in the adjuvant treatment of patients with stage IB to IIIA non–small cell lung cancer following surgical resection, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Pasi A. Jänne, MD, PhD, discovered a new way to treat lung cancer by following his intuition and staying flexible to pursue opportunities as they arise

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.